1 recruiting, 1 unknown. 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Unknown 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Glioblastoma Multiform: new trials by email Literature Review of Glioblastoma Multiform trials Research Report on Glioblastoma Multiform
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma TLX-101-Tx + Lomustine, TLX101-Tx - Neoplastic Disease, Glioblastoma | Phase 3 | Recruiting | Telix Pharmaceuticals (Innovations) Pty Limited | 50 | 2025-11-02 | 2026-08-11 |
| Nk Cell Therapy for Recurrent Glioblastoma Multiform Patients NK cell therapy - Glioblastoma Multiform, Recurrent Glioblastoma | Phase 1 | Unknown | Royan Institute | 5 | 2021-08-01 | 2021-11-22 |
Glioblastoma (2) · Brain Neoplasms (1) · Central Nervous System Neoplasms (1) · Neoplasm Recurrence, Local (1) · Neoplasms (1)
Astrocytoma (2) · Glioma (2) · Neoplasms by Histologic Type (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Glandular and Epithelial (2) · Neoplasms, Nerve Tissue (2) · Neoplasms, Neuroepithelial (2) · Neuroectodermal Tumors (2) · Brain Diseases (1) · Central Nervous System Diseases (1) · Neoplasms (1) · Neoplasms by Site (1) · Neoplastic Processes (1) · Nervous System Diseases (1) · Nervous System Neoplasms (1)
Lomustine (1)
Royan Institute (1) · Telix Pharmaceuticals (Innovations) Pty Limited (1)
Australia (1) · Austria (1) · Belgium (1) · Iran (1) · Netherlands (1)
Abolhossein Shahverdi, PhD (1) · Amirali Hamidieh, MD,PhD (1) · Marzieh Ebrahimi, PhD (1) · Monire Mohammad, MSc (1) · Niloufar Shayan Asl, MSc (1) · Zohreh Habibi, M.D (1)
2025 (1)